Table 2.
Immunogenicity in both groups
| Influenza strain and immunogenicity endpointa | Healthy children (N = 68) | Children with recurrent wheezing (N = 62) | P |
|---|---|---|---|
| A/California(H1N1) | |||
| Seroconversion (n [% (95% CI)]) | 47 (69.12 [58.14–80.10]) | 41 (66.13 [54.35–77.91]) | 0.7159 |
| Seroprotection (n [% (95% CI)]), day 28 | 50 (75.53 [63.04–84.02]) | 46 (74.19 [63.30–85.09]) | 0.9314 |
| GMT (95% CI), day 0 | 2.94 (1.80–4.54) | 5.93 (3.56–9.53) | |
| GMT (95% CI), day 28 | 52.91 (40.45–69.12) | 56.37 (38.89–81.31) | |
| GMTR | 12.69 | 7.28 | <0.0001 |
| A/Perth(H3N2) | |||
| Seroconversion (n [% (95% CI)]) | 55 (80.88 [71.54–90.23]) | 46 (74.19 [63.30–85.09]) | 0.3602 |
| Seroprotection (n [% (95% CI)]), day 28 | 57 (83.82 [75.07–92.58]) | 48 (77.42 [67.01–87.83]) | 0.3548 |
| GMT (95% CI), day 0 | 3.96 (2.43–6.15) | 1.95 (1.01–3.32) | |
| GMT (95% CI), day 28 | 62.29 (46.30–83.68) | 58.84 (42.40–81.51) | |
| GMTR | 11.77 | 19.29 | <0.0001 |
| B/Brisbane | |||
| Seroconversion (n [% (95% CI)]) | 42 (61.76 [50.21–73.32]) | 38 (61.29 [49.17–73.41]) | 0.7443 |
| Seroprotection (n [% (95% CI)]), day 28 | 50 (75.53 [63.04–84.02]) | 44 (70.97 [59.67–82.27]) | 0.7444 |
| GMT (95% CI), day 0 | 11.78 (9.38–14.73) | 9.12 (6.66–12.38) | |
| GMT (95% CI), day 28 | 49.35 (40.17–60.59) | 43.88 (35.76–53.79) | |
| GMTR | 2.94 | 3.43 | 0.1777 |
a
Seroconversion was defined as a prevaccination antibody titer of ≤1:10 and a postvaccination titer of ≥1:40. Seroprotection was defined as a postvaccination antibody titer of ≥1:40. CI, confidence interval; GMTR, geometric mean of post- to prevaccination titer ratios; GMT, geometric mean titer.